Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms
Launched by UNIVERSITY HOSPITAL, GRENOBLE · Aug 31, 2021
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying colorectal cancer, which is one of the most common types of cancer worldwide. The main focus is to understand why some patients do not respond well to chemotherapy treatments. Researchers want to develop a special model using tumor samples taken from patients who have not yet started chemotherapy. By examining these samples, they hope to learn more about the role of the immune system in how tumors resist treatment. This could lead to new ways to predict how well a patient might respond to chemotherapy and help create more personalized treatment plans.
To participate in this study, you must be at least 18 years old and have been diagnosed with colorectal adenocarcinoma. You should also be scheduled for surgery to remove the tumor and have not received any chemotherapy before. However, certain individuals, such as pregnant women or those with specific infections, may not be eligible. If you join the trial, you'll be contributing to important research that could improve treatment options for future colorectal cancer patients, ultimately aiming to enhance their care and outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female over 18 years old.
- • Managed at the CHUGA for a colorectal adenocarcinoma
- • With an indication for immediate surgical resection as part of the care.
- • Patient naive from neo-adjuvant chemotherapy
- • Patient did not object to the CRC-ORGA-2 study
- Exclusion Criteria:
- • Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress).
- • Patients with positive HIV, HBV, HCV serology.
About University Hospital, Grenoble
The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grenoble, , France
Patients applied
Trial Officials
GAEL ROTH, MD, PHD
Principal Investigator
university hospital of Grenoble alpes
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials